Published research on Propranolol hydrochloride
4 peer-reviewed publications on Propranolol hydrochloride in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.
- Clinical trial
Propranolol monotherapy in angiosarcoma: a window-of-opportunity study (PropAngio)
In 14 patients with angiosarcoma treated with propranolol monotherapy for 3 to 6 weeks before standard care, two patients showed clinical response and none showed histologic response, and the trial did not demonstrate clinical efficacy of propranolol monotherapy.
- Clinical trial
In a 3 + 3 dose-escalation study of nine patients with treatment-naive metastatic melanoma, propranolol combined with pembrolizumab produced no dose-limiting toxicities and an objective response rate of 78%.
- Clinical trial
In a triple-blind placebo-controlled trial of 60 breast cancer patients, 7 days of preoperative propranolol downregulated mesenchymal gene expression in the primary tumor without affecting epithelial gene expression and was associated with changes in intratumoral immune cell infiltration.
- Observational
Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study
In a prospective cohort of 53 patients with stage IB to IIIA melanoma, off-label propranolol use at diagnosis was inversely associated with recurrence after adjustment for prognostic factors (hazard ratio 0.18, 95% CI 0.04 to 0.89).
Propranolol hydrochloride in the catalog (specifications, pack sizes, Certificate of Analysis)